查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601191

药物安全检测和药物安全软体市场：按产品、临床试验、分销和最终用户 - 2025-2030 年全球预测

Pharmacovigilance & Drug Safety Software Market by Product (Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software), Clinical Trial (Phase I, Phase II, Phase III), Distribution, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年药物安全检测与药物安全软体市值为5.521亿美元，预计2024年将达到6.2931亿美元，到2030年将成长至14.2924亿美元，复合年增长率为14.55%。

药物安全检测和药物安全软体透过确保对上市后药物安全性的持续监测和评估，在医疗保健和製药行业中发挥重要作用。对该软体的需求源于不断增加的药物不良反应 (ADR) 发生率以及需要係统记录和分析的严格政府法规。该软体具有广泛的应用范围，包括药物开发公司、CRO、製药公司和监管机构，主要最终用户是专注于患者安全和合规性的医疗保健专业人员和研究人员。市场成长是由人工智慧和机器学习等技术进步所推动的，这些技术进步增强了资料处理和预测分析能力。日益全球化和新药发现的迅速增加进一步推动了需求。整合真实世界资料（RWD）以实现更准确的安全概况，以及开发云端基础的平台以改善各相关人员之间的可访问性和协作，存在新的机会。然而，资料隐私问题、高实施成本和监管合规复杂性等挑战可能会阻碍市场成长。此外，法规的地区差异需要灵活的软体解决方案并增加了复杂性。这个产业的创新时机已经成熟，是增强讯号检测技术和实施区块链技术以确保资料完整性的完美领域。这些创新可以透过简化业务和提高透明度来提供竞争优势。由于大量不断增长的供应商提供类似的解决方案，市场仍然竞争激烈且细分。因此，透过创新和客製化实现差异化是关键。公司应专注于使用者友善的介面和可扩展的解决方案，以服务小型到大型企业，并继续推动监管指南的明确性，以简化合规流程。透过专注于这些关键领域，公司可以有效克服药物安全检测和药物安全软体市场的挑战并利用潜在机会。

主要市场统计
基准年[2023] 5.521 亿美元
预测年份 [2024] 62931万美元
预测年份 [2030] 1,429.24 百万美元
复合年增长率（%） 14.55%

市场动态：揭示快速发展的药物安全检测和药物安全软体市场的关键市场洞察

供需的动态交互作用正在改变药物安全检测和药物安全软体市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 不良反应和药物毒性发生率增加
    • 越来越需要减少审阅医学文献的时间
    • 高度监管的药物安全检测领域
  • 市场限制因素
    • 实施昂贵的药物安全检测和药物安全软体
  • 市场机会
    • 医疗公司增加研发（R&D）投资
    • 将人工智慧和机器学习模型整合到药物安全检测和药物安全软体中
  • 市场问题
    • 新兴国家对药物不良反应 (ADR) 缺乏认识、缺乏训练和报告不足

波特五力：驾驭药物安全检测与药物安全软体市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解药物安全检测和药物安全软体市场的外部影响

外部宏观环境因素在塑造药物安全检测和药物安全软体市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解药物安全检测和药物安全软体市场的竞争格局

药物安全检测和药物安全软体市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵：药物安全检测与药物安全软体市场供应商的绩效评估

FPNV 定位矩阵是评估药物安全检测和药物安全软体市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。四个象限清楚且准确地划分供应商，帮助使用者辨识最能满足其策略目标的合作伙伴和解决方案。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾，包括行业主要企业的大量资料。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 不良反应和药物毒性发生率增加
      • 人们越来越需要减少审查医学文献以获取总结报告和论文的时间。
      • 高度监管的药品安全监测领域
    • 抑制因素
      • 药物安全检测和药物安全软体的部署成本高昂
    • 机会
      • 医疗公司增加研发（R&D）投资
      • 将人工智慧和机器学习模型整合到药物安全检测和药物安全软体中
    • 任务
      • 新兴国家缺乏对药物不良反应 (ADR) 的认识、培训和报告
  • 市场区隔分析
    • 产品：增加药品安全审核软体的使用，确保遵守药品安全监理法规
    • 最终用户：药物安全检测和药物安全软体为合约研究机构处理临床试验资料并提供高级报告功能的潜力
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化

第六章药物安全检测与药物安全软体市场：副产品

  • 介绍
  • 不利事件通报软体
  • 药品安全审核软体
  • 完全整合的软体
  • 问题追踪软体

第七章药物安全检测与药物安全软体市场：透过临床试验

  • 介绍
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段
  • 临床前

第八章药物安全检测与药物安全软体市场：依分布

  • 介绍
  • 云
  • 本地

第九章药物安全检测与药物安全软体市场：依最终使用者分类

  • 介绍
  • 业务流程外包公司
  • 合约研究组织
  • 製药和生物技术公司
  • 药品安全监测服务供应商

第十章美洲药物安全检测与药物安全软体市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太药物安全检测与药物安全软体市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲药物安全检测和药物安全软体市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • RxLogix 公司宣布与欧洲药品管理局 (EMA) 建立突破性伙伴关係，提供尖端安全解决方案
    • JNPMEDI发布药品安全管理解决方案“Maven Safety”

公司名单

  • Clinevo Technologies Private Limited
  • United BioSource LLC
  • Indegene Inc.
  • IQVIA Inc.
  • Accenture PLC
  • Freyr Software Services Pvt. Ltd.
  • Tepsivo Oy
  • ArisGlobal LLC
  • Clarivate
  • PureSoftware Limited
  • Anju Software, Inc.
  • TriNetX, LLC
  • Cognizant Technology Solutions Corporation
  • AB Cube SAS
  • Oracle Corporation
  • 4C Pharma Solutions
  • Wipro Limited
  • NUVO Consultancy
  • Infosys Limited
  • Cloudbyz, Inc.
  • Ennov SAS
  • Certara, Inc.
  • Sarjen Systems Private Limited
  • Sparta Systems, Inc.
  • Ergomed PLC
  • Extedo GmbH
Product Code: MRR-030EE4851600

The Pharmacovigilance & Drug Safety Software Market was valued at USD 552.10 million in 2023, expected to reach USD 629.31 million in 2024, and is projected to grow at a CAGR of 14.55%, to USD 1,429.24 million by 2030.

Pharmacovigilance and drug safety software plays a crucial role in the healthcare and pharmaceutical industries by ensuring the continual monitoring and assessment of drug safety, post-marketing. The necessity for this software arises from the increasing incidence of adverse drug reactions (ADRs) and stringent government regulations requiring systematic documentation and analysis. The application of this software spans drug development companies, CROs, pharmaceutical companies, and regulatory bodies, with the primary end-users being healthcare professionals and researchers focusing on patient safety and compliance. Market growth is driven by technological advancements such as AI and machine learning, which enhance data processing and predictive analytics capabilities. Increasing globalization and the surge in new drug discoveries further fuel the demand. Emerging opportunities exist in the integration of real-world data (RWD) for more accurate safety profiles and the development of cloud-based platforms to improve accessibility and collaboration across various stakeholders. However, challenges such as data privacy concerns, high implementation costs, and the complexity of regulatory compliance can hinder market growth. Furthermore, regional differences in regulations require flexible software solutions, adding layers of complexity. The industry is ripe for innovation, with the best areas being the enhancement of signal detection methodologies and the incorporation of blockchain technology to ensure data integrity. These innovations can provide competitive advantages by streamlining operations and enhancing transparency. While the market is growing, it remains competitive and fragmented, with numerous vendors offering similar solutions. Thus, differentiation through innovation and customization is key. Companies should focus on user-friendly interfaces and scalable solutions to cater to small and large enterprises alike, while continually lobbying for clearer regulatory guidelines to simplify compliance processes. By focusing on these critical areas, businesses can effectively navigate challenges and capitalize on the potential opportunities within the pharmacovigilance and drug safety software market.

KEY MARKET STATISTICS
Base Year [2023] USD 552.10 million
Estimated Year [2024] USD 629.31 million
Forecast Year [2030] USD 1,429.24 million
CAGR (%) 14.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacovigilance & Drug Safety Software Market

The Pharmacovigilance & Drug Safety Software Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Incidence of ADR and Drug Toxicity
    • Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
    • Highly Regulated Pharmacovigilance Space
  • Market Restraints
    • Expensive Deployment of Pharmacovigilance & Drug Safety Software
  • Market Opportunities
    • Increasing Investment in Research and Development (R&D) by Healthcare Companies
    • Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
  • Market Challenges
    • Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacovigilance & Drug Safety Software Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacovigilance & Drug Safety Software Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacovigilance & Drug Safety Software Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacovigilance & Drug Safety Software Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacovigilance & Drug Safety Software Market

A detailed market share analysis in the Pharmacovigilance & Drug Safety Software Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacovigilance & Drug Safety Software Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacovigilance & Drug Safety Software Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pharmacovigilance & Drug Safety Software Market, highlighting leading vendors and their innovative profiles. These include Clinevo Technologies Private Limited, United BioSource LLC, Indegene Inc., IQVIA Inc., Accenture PLC, Freyr Software Services Pvt. Ltd., Tepsivo Oy, ArisGlobal LLC, Clarivate, PureSoftware Limited, Anju Software, Inc., TriNetX, LLC, Cognizant Technology Solutions Corporation, AB Cube S.A.S., Oracle Corporation, 4C Pharma Solutions, Wipro Limited, NUVO Consultancy, Infosys Limited, Cloudbyz, Inc., Ennov SAS, Certara, Inc., Sarjen Systems Private Limited, Sparta Systems, Inc., Ergomed PLC, and Extedo GmbH.

Market Segmentation & Coverage

This research report categorizes the Pharmacovigilance & Drug Safety Software Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Adverse Event Reporting Software, Drug Safety Audits Software, Fully Integrated Software, and Issue Tracking Software.
  • Based on Clinical Trial, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-clinical.
  • Based on Distribution, market is studied across On-Cloud and On-Premise.
  • Based on End User, market is studied across Business Process Outsourcing Firms, Contract Research Organizations, Pharma & Biotech Companies, and Pharmacovigilance Service Providers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Incidence of ADR and Drug Toxicity
      • 5.1.1.2. Increasing Need to Reduce Time Spent Reviewing Medical Literature for Aggregate Reports and Articles
      • 5.1.1.3. Highly Regulated Pharmacovigilance Space
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive Deployment of Pharmacovigilance & Drug Safety Software
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing Investment in Research and Development (R&D) by Healthcare Companies
      • 5.1.3.2. Integration of AI and Machine Learning Models in Pharmacovigilance & Drug Safety Software
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Awareness, Training, and Underreporting of Adverse Drug Reactions (ADRs) in Developing Countries
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing usage of drug safety audit software to ensure compliance with pharmacovigilance regulations
    • 5.2.2. End User: Potential of pharmacovigilance & drug safety software among contract research organizations for handling clinical trial data and offering advanced reporting capabilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Pharmacovigilance & Drug Safety Software Market, by Product

  • 6.1. Introduction
  • 6.2. Adverse Event Reporting Software
  • 6.3. Drug Safety Audits Software
  • 6.4. Fully Integrated Software
  • 6.5. Issue Tracking Software

7. Pharmacovigilance & Drug Safety Software Market, by Clinical Trial

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-clinical

8. Pharmacovigilance & Drug Safety Software Market, by Distribution

  • 8.1. Introduction
  • 8.2. On-Cloud
  • 8.3. On-Premise

9. Pharmacovigilance & Drug Safety Software Market, by End User

  • 9.1. Introduction
  • 9.2. Business Process Outsourcing Firms
  • 9.3. Contract Research Organizations
  • 9.4. Pharma & Biotech Companies
  • 9.5. Pharmacovigilance Service Providers

10. Americas Pharmacovigilance & Drug Safety Software Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacovigilance & Drug Safety Software Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance & Drug Safety Software Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. RxLogix Corporation Announces Landmark Partnership with the European Medicines Agency (EMA) for a Cutting-Edge Safety Solution
    • 13.3.2. Launch by JNPMEDI of 'Maven Safety,' a drug safety management solution

Companies Mentioned

  • 1. Clinevo Technologies Private Limited
  • 2. United BioSource LLC
  • 3. Indegene Inc.
  • 4. IQVIA Inc.
  • 5. Accenture PLC
  • 6. Freyr Software Services Pvt. Ltd.
  • 7. Tepsivo Oy
  • 8. ArisGlobal LLC
  • 9. Clarivate
  • 10. PureSoftware Limited
  • 11. Anju Software, Inc.
  • 12. TriNetX, LLC
  • 13. Cognizant Technology Solutions Corporation
  • 14. AB Cube S.A.S.
  • 15. Oracle Corporation
  • 16. 4C Pharma Solutions
  • 17. Wipro Limited
  • 18. NUVO Consultancy
  • 19. Infosys Limited
  • 20. Cloudbyz, Inc.
  • 21. Ennov SAS
  • 22. Certara, Inc.
  • 23. Sarjen Systems Private Limited
  • 24. Sparta Systems, Inc.
  • 25. Ergomed PLC
  • 26. Extedo GmbH

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ADVERSE EVENT REPORTING SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DRUG SAFETY AUDITS SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY FULLY INTEGRATED SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ISSUE TRACKING SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-CLOUD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY ON-PREMISE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY BUSINESS PROCESS OUTSOURCING FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PHARMACOVIGILANCE SERVICE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 195. PHARMACOVIGILANCE & DRUG SAFETY SOFTWARE MARKET, FPNV POSITIONING MATRIX, 2023